The stock of Wockhardt has gone up due to Zayinch. Zaynich is a trademarked antibiotic drug meant to act against all major superbugs. The success of Ozempic made the Danish drugmaker the most valuable company in Europe the way Ozempic did charm Novo Nordisk such way Zaynich can do to Wockhardt.
In AGM speech, founder Habil Khorakiwala informed that the Zaynich drug is a proprietary new chemical entity and one of its kind antibiotics discovered in the last 50 years. Zaynich is going through the third phase of clinical trials globally and is expected to complete by the final year.
The company is expecting to receive global approval for Zaynich by the financial year 26. Zaynich has a market potential of $25 billion because of the increasing antibiotic resistance of the global population. This step is huge for the company.
Indian Pharma company is making the huge promise of successful drug delivery it has led Madhusudan Kela and Prashant Jain to invest in Wockhardt’s QIP issue of 480 crore rs in March. This is not surveyed territory for Indian Pharma investors as no Indian Pharma company has made such an impact to deliver success in innovative drug discovery.
The stock of Wockhardt has increased more than triple in the past year. The price of stocks has rinsed due to positive news of Zaynich related to the company’s R&D effort
